The Effect of Human Papillomavirus Vaccination on Recurrence Rates in HIV Positive Patients Treated for Anal Condylomata.

Trial Profile

The Effect of Human Papillomavirus Vaccination on Recurrence Rates in HIV Positive Patients Treated for Anal Condylomata.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2016

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Anal cancer; Anal intraepithelial neoplasia; Cervical cancer; Condylomata acuminata; Human papillomavirus infections; Penile cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jun 2016 Status changed from recruiting to completed.
    • 27 Jul 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top